| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004101 | American Journal of Ophthalmology | 2009 | 7 Pages |
Abstract
These findings, although insufficient to consider “off-label” treatment with intravitreal infliximab, provide in vivo evidence of a pathogenetic link of locally produced and/or acting TNF to neovascular AMD. A randomized study of consecutive intravitreal injections of infliximab for AMD may be warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Panagiotis G. Theodossiadis, Vasilios S. Liarakos, Petros P. Sfikakis, Ioannis A. Vergados, George P. Theodossiadis,